IMPORTANCE Despite 3 decades of study, there remains ongoing debate regarding whether vasectomy is associated with prostate cancer.
V asectomy is a highly efficacious long-term contraceptive method that involves a simple outpatient procedure under local anesthetic. It is less expensive and has a lower risk of complications compared with tubal ligation, the analogous female surgical sterilization procedure. 1, 2 Although 43 million women worldwide rely on their partner's vasectomy for contraception, 3, 4 vasectomy is still considered to be underused in the United States, with only 8% to 12% of couples using vasectomy for birth control. [4] [5] [6] In the late 1980s and early 1990s, several reports began to emerge of an epidemiologic association between vasectomy and the risk of prostate cancer. [7] [8] [9] [10] [11] This finding ignited a controversy captured in numerous editorials, reviews, and original research articles supporting or refuting the association. Several meta-analyses of this association have been performed, but they did not bring closure to the debate. One older meta-analysis pooling 5 cohort studies and 17 case-control studies found a significant association between vasectomy and prostate cancer.
12
Meanwhile, 2 more recent meta-analyses of cohort studies found no statistically significant association, although the CIs of pooled effect estimates precluded definitive conclusions. [13] [14] [15] Moreover, none of these meta-analyses included a sufficient number of studies with a low risk of bias to analyze them as a separate subset, nor were the meta-analyses able to evaluate the association between vasectomy and risk of high-grade, advanced-stage, and fatal prostate cancer. Recently, several large, high-quality analyses demonstrating either an association 16, 17 or no association [18] [19] [20] between vasectomy and prostate cancer have reignited the controversy. With the aim of shedding some light onto a debate that is 3 decades old, we conducted a systematic review of the literature and performed a meta-analysis, with particular attention to study quality, to determine if there is an association between vasectomy and any prostate cancer, high-risk prostate cancer, advanced prostate cancer, and lethal prostate cancer.
Methods

Research Question
Is there an association between vasectomy and a subsequent diagnosis of prostate cancer? More specifically, is vasectomy associated with a diagnosis of any prostate cancer, high-risk prostate cancer, advanced prostate cancer, and/or fatal prostate cancer? The Mayo Clinic Institutional Review Board waived the need for review of this study.
Types of Studies
We included cohort, case-control, and cross-sectional studies. Case series lacking comparator groups were excluded. Other publications, including editorials, commentaries, review articles, and those not subject to peer review (ie, reports of data from Vital Statistics and dissertations or theses), were excluded. When there was more than 1 publication resulting from the same patient cohort, we selected a single representative study, with a preference for more contemporary publications and publications with a larger number of patients and more reliable methods of exposure and outcome ascertainment.
Types of Participants and Exposure
We reviewed studies reporting on men of any age who underwent vasectomy compared with those who did not undergo vasectomy. Vasectomy exposure was determined by administrative and clinical health records, survey results, and/or patient recall.
Outcome Measures
The primary outcome was any subsequent diagnosis of prostate cancer. Secondary outcomes included the diagnoses of high-grade prostate cancer (based on individual study definition, typically Gleason score ≥8), advanced prostate cancer (based on individual study definition, typically T3/4, N+, or M+), and fatal prostate cancer.
ciation between vasectomy and any prostate cancer outcome, or provided sufficient data for this estimate to be calculated. One of us (B.B.) performed all data abstraction, including evaluation of study characteristics, risk of bias, and outcome measures, with independent verification performed by another one of us (C.J.D.W.).
Assessment of Risk of Bias
We used the Newcastle-Ottawa Scale for assessment of risk of bias. This scale assesses risk of bias in the following 3 domains 23 : selection of the study groups, comparability of groups, and ascertainment of exposure and outcome. 24 Studies with scores of less than 4 were considered to have a high risk of bias, those with scores of 4 to 6 an intermediate risk of bias, and those with scores of 7 or more a low risk of bias.
Measures of Treatment Effect
Measures of treatment effect varied among study designs. Among cross-sectional and case-control studies, we pooled odds ratios (ORs). In each case, we examined unadjusted and adjusted measures of effect separately. Among cohort studies, we first pooled ratio measures of effect (including hazard ratios [HRs] , rate ratios [RRs] , and ORs). 25, 26 Subsequently, we performed subgroup analysis using only studies that reported time-to-event data (HRs).
Assessment of Heterogeneity
We identified heterogeneity using the Q test, estimated it using the DerSimonian-Laird method, and quantified it using I 2 values. 27 Furthermore, we used random-effects models for each of our analyses, given the identified clinical heterogeneity.
Assessment of Reporting Bias
We assessed publication bias for outcomes with more than 10 included studies using funnel plots.
Data Synthesis
Meta-analysis was performed using Review Manager, version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration). We used the inverse variance technique for pooling of measures of effect. Owing to the clinical heterogeneity inherent in our data, random-effects models were used for all metaanalyses. A sensitivity analysis was performed to determine if excluding any individual study altered our results.
Subgroup and Exploratory Analyses
We performed a priori subgroup analyses. First, as already mentioned, we examined cohort studies that used a time-toevent analysis separately. Second, we examined studies identified as having a low risk of bias. Third, we evaluated the studies that provided effect estimates stratified by time since vasectomy and age at which vasectomy was performed.
We also performed post hoc subgroup analyses. First, we examined cohort studies in which all patients were following a prostate-specific antigen (PSA) screening protocol or in which PSA screening was accounted for in multivariable models. Second, we examined cohort studies in which PSA screening was not performed or was very uncommon.
Finally, to facilitate interpretation of relative effect estimates for clinicians and policymakers, the pooled effect estimate from the meta-analysis was used to estimate the absolute risk increase, the number needed to harm, and the population attributable fraction. For these calculations, the lifetime risk of prostate cancer was considered to be 12.9% 28 and the probability of undergoing vasectomy was 10%. 4, 5 Results and Evidence Synthesis Our literature search identified 433 unique references (Figure 1) . After a full-text review of 115 manuscripts, 53 were selected for inclusion. The reasons for exclusion are summarized in Figure 1 and eAppendix 2 in the Supplement.
Description of Studies
Among the 53 included studies, 16 were cohort studies (2 563 519 participants), 11, [16] [17] [18] [19] [20] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] 33 were case-control studies (44 536 participants), 8, 9 ,39-68 and 4 were crosssectional studies (12 098 221 participants). [69] [70] [71] [72] Although most studies were population-or registry-based analyses, several articles presented single-or multiple-institution analyses (Table) . 8, 9, 11, [16] [17] [18] [19] [20] Duration of follow-up varied widely among cohort studies, with a minimum of 1.8 years and a maximum of 24 years. In general, the patients with and the patients without a history of vasectomy were similar in age among cohort studies. Among the case-control studies, the patients with and the patients without a diagnosis of cancer were generally similar in age, although, in some analyses, patients who received a diagnosis of prostate cancer were older. 39, 40 The risk-adjustment approach varied across studies (eTable 1 in the Supplement).
Assessment of Risk of Bias
Assessment of risk of bias was performed according to study methods (eTable 2 in the Supplement). Nine of the cohort studies (56%) were assessed as having a low risk of bias. [16] [17] [18] [19] [20] 29, 32, 34, 38 Exposure was ascertained by self-report or questionnaire results in several of these studies. Eight of 16 cohort studies (50%) accounted for PSA testing and/or health-seeking behavior. [16] [17] [18] [19] 32, 33, 37, 38 Most case-control studies (26 [79%])
were considered to have a moderate to high risk of bias. 8, 9, 39, 40, 42, 43, [45] [46] [47] [48] 51, 52, [54] [55] [56] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] Although cases were typically well defined, the use of hospital-based instead of community-based controls was considered a potential source of bias among many case-control studies. Ascertainment of exposure was also a common source of bias among casecontrol studies. All 4 cross-sectional studies were thought to have a moderate to high risk of bias.
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All Prostate Cancer
To assess the association between vasectomy and any diagnosis of prostate cancer, we first pooled results from cohort studies ( Figure 2 ). Among the 13 of 16 cohort studies reporting on 2 563 519 patients that used adjusted measures of effect, 11, [16] [17] [18] [19] [20] 29, [31] [32] [33] [35] [36] [37] we found a small but statistically significant increased risk of any diagnosis of prostate cancer among patients with a history of vasectomy (adjusted RR, 1.08; 95% CI, 1.02-1.14; P = .006; I 2 = 63%) ( Figure 2A) . A similar outcome was observed among cohort studies using a time-toevent analysis (9 studies; adjusted HR, 1.09; 95% CI, 1.03-1.15; P = .004; I 2 = 70%) (eFigure 1 in the Supplement).
11, [16] [17] [18] [19] [20] 31, 32, 35 The effect estimate among studies deemed at low risk of bias remained statistically significant but was closer to the null (7 studies; adjusted RR, 1.05; 95% CI, 1.02-1.09; P < .001; Figure 2B ). [16] [17] [18] [19] [20] 29, 32 Results were not meaningfully different when abstracts were excluded (eTable 3 in the Supplement). Among cohort studies in which all patients explicitly underwent PSA screening (as in the screening arm of the PLCO [Prostate, Lung, Colorectal and Ovarian] Cancer Screening trial) 17 or in which PSA screening was accounted for in multivariable models, the association between vasectomy and prostate cancer was consistent with our overall findings (6 studies; adjusted RR, 1.06; 95% CI, 1.02-1.09; P < .001; I 2 =16%) (eFigure 2 in the Supplement). 16, 17, 19, 32, 33, 37 Furthermore, among studies that reported on populations in which PSA screening was not performed or very uncommonly performed, we observed no association between vasectomy and prostate cancer, although this finding was limited by few studies and significant heterogeneity (2 studies; adjusted RR, 1.26; 95% CI, 0.51-3.07; P = .62; I 2 = 84%).
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We then separately assessed the association between vasectomy and any diagnosis of prostate cancer among casecontrol studies ( Figure 3 ). Meta-analysis of studies reporting adjusted ORs demonstrated a statistically significant association between vasectomy and prostate cancer (17 studies; adjusted OR, 1.31; 95% CI, 1.12-1.53; P < .001; I 2 =6 6 % ) ( Figure 3A) . 9, [39] [40] [41] [42] [43] [44] 48, 49, 51, 53, [56] [57] [58] 61, 63, 73 When we restricted analysis to 6 studies deemed to have low risk of bias, there was no significant association (adjusted OR, 1.06; 95% CI, 0.88-1.29; P =.54;I 2 = 37%) ( Figure 3B ). 41, 44, 49, 53, 57, 73 There were no cross-sectional studies reporting adjusted measures of effect. Analyses of cohort, case-control, and cross-sectional studies reporting unadjusted measures of effect were performed for completeness and are summarized in eAppendix 3 and eFigure 3 in the Supplement. These results did not meaningfully alter conclusions. In the sensitivity analysis, excluding any individual study did not alter the results in each of the respective meta-analyses.
Secondary Outcomes
Among cohort studies, there was no statistically significant association noted between vasectomy and the diagnosis of high-grade prostate cancer (6 studies; adjusted HR, 1.03; 95% CI, 0.89-1.21; P =. 67 ;I 2 = 55%), 16, [18] [19] [20] 31, 38 advanced prostate cancer (6 studies; adjusted HR, 1.08; 95% CI, 0.98-1.20; P = .11; I 2 = 18%), 16, [18] [19] [20] 31, 38 or fatal prostate cancer (5 studies; adjusted HR, 1.02; 95% CI, 0.92-1.14; P = .68; I 2 =26%) ( Figure 4) . 16, [18] [19] [20] 38 Five case-control studies assessed the association between vasectomy and prostate cancer, stratified by stage. [41] [42] [43] [44] 46 The varied definitions of advanced prostate cancer in these studies precluded meta-analysis of these results. Qualitatively, there was a greater association between vasectomy and low-risk prostate cancer than between vasectomy and advanced disease among these studies. Meanwhile, a single case-control study assessed the association between vasectomy and fatal prostate cancer and found no 
Duration of Exposure and Age at Vasectomy
Six cohort studies, 11, 16, 20, [29] [30] [31] 15 case-control studies, 8, 9, [40] [41] [42] [43] [44] [46] [47] [48] [50] [51] [52] 73 and 1 cross-sectional study 70 reported on the association of time since vasectomy with the development of prostate cancer (eTable 4 in the Supplement). Of these, 1 cohort study 11 and 6 case-control studies 8, 9, 40, [46] [47] [48] suggested a stronger association between vasectomy and prostate cancer with increasing time since vasectomy, although in several instances the CIs of the individual strata included unity and formal tests for trend were only performed in 3 studies. 8, 9, 48 The remainder of these studies did not find any such biological gradient associated with time since vasectomy. 16, 20, [29] [30] [31] [41] [42] [43] [44] [49] [50] [51] [52] 70, 73 Four cohort studies 16, 20, 30, 31 and 11 case-control studies [40] [41] [42] [43] [44] 46, [48] [49] [50] [51] 73 reported effect estimates stratified by age at vasectomy (eTable 5 in the Supplement). Of these, 1 cohort study 20 and 4 case-control studies 42, 46, 48, 49 found that the association between vasectomy and prostate cancer was stronger among men who had their vasectomy performed at a younger age. Conversely, 1 cohort study 31 and 1 case-control study 40 found that men who were older when they had their vasectomy were at greater risk for incident prostate cancer. The remainder of these studies didnot find any association of age at vasectomy with development of prostate cancer. 16, 30, 41, 43, 44, 50, 51, 73 Effect estimates for time since vasectomy and age at vasectomy could not be pooled owing to the varying types of effect estimates and time intervals used by the individual studies.
Publication Bias
We assessed publication bias using funnel plots comparing effect size and measure of precision of the effect size among case-control studies reporting unadjusted and adjusted Heterogeneity τ Test for overall effect: z = 3.34 (P <.001)
Cohort studies with low risk of bias B Data were pooled separately by study design type using random-effects models; the inverse variance technique was used for pooling of measures of effect. NR indicates not reported.
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Original Investigation Research jamainternalmedicine.com (Reprinted) JAMA Internal Medicine September 2017 Volume 177, Number 9 1281 measures of effect and cohort studies reporting adjusted measures of effect (eFigure 4 in the Supplement). There was potential publication bias among cohort studies, with a relative paucity of small studies demonstrating a large increased risk, and among case-control studies reporting adjusted measures of effect, with a relative paucity of small studies demonstrating no increased risk.
Exploratory Estimations
Using the pooled effect estimate from the meta-analysis of cohort studies with a low risk of bias, we found that the absolute increase in lifetime risk of prostate cancer is estimated to be 0.6% (95% CI, 0.3%-1.2%), that the number needed to harm (assuming a causal association, the number of men who would need to undergo vasectomy to result in 1 incident case of prostate cancer) is estimated to be 156, and that the population attributable fraction (assuming a causal association, the proportion the lifetime risk of prostate cancer would be reduced if no vasectomies were performed) is estimated to be 0.5% (95% CI, 0.2%-0.9%) (eAppendix 4 in the Supplement).
Discussion
To date, the potential for bias in the studies on the association between vasectomy and prostate cancer has been a major focus of criticism of this body of literature. Accordingly, we found that the effect estimates of the association between vasectomy and prostate cancer were increasingly closer to the null when examining studies with increasingly robust study design and study quality. In our meta-analysis of cohort studies Case-control studies with low risk of bias B Data were pooled separately by study design type using random-effects models; the inverse variance technique was used for pooling of measures of effect. NA indicates not available.
Research Original Investigation
The Association Between Vasectomy and Prostate Cancer with a low risk of bias, we found a 5% increase in the risk of incident prostate cancer with vasectomy. This result was not driven by any single study alone. Meanwhile, the associations between vasectomy and high-grade, advanced, and fatal prostate cancer were not statistically significant, although the point estimates were similar to those for total diagnoses of prostate cancer. If assuming causality, for the individual patient, the effect estimate for overall prostate cancer corresponds to a 0.6% absolute increase in lifetime risk of incident prostate cancer, or a number needed to harm of 156. At the population level, only 0.5% of prostate cancers are estimated to be associated with vasectomy. It is questionable whether such a small increased risk is important to the public. Although meta-analyses have been previously performed, an analysis of cohort studies with a low risk of bias has only recently been possible, with 6 of 7 such studies reported within the last 3 years. [16] [17] [18] [19] [20] 32 One meta-analysis published in 2002 pooled data from 5 cohort and 17 case-control studies and found a significant association between vasectomy and prostate cancer. 12 Meanwhile, 2 more recent metaanalyses combined data from 9 cohort studies and found no significant association but had wide CIs. 14,15 Another metaanalysis combined data from 10 cohort studies and found no association, but the lower limit of its CI barely crossed 1 (RR, 1.11; 95% CI, 0.98-1.27). 13 Our meta-analysis, which included 53 studies, was able to separately analyze case-control, crosssectional, and cohort studies and was well powered and achieved effect estimates with narrow CIs. In our assessment, most of the 33 case-control studies, all 4 of the cross-sectional studies, and almost half of the 16 Fatal prostate cancer C Data were pooled separately by study design type using random-effects models; the inverse variance technique was used for pooling of measures of effect.
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Original cohort studies had a moderate to high risk of bias. Accordingly, the point estimates for association between vasectomy and prostate cancer were furthest from the null among pooled analyses of case-control and cross-sectional studies. Publication bias might also have contributed, in part, based on funnel plots. In contrast, the observed association was smaller in magnitude in the pooled analysis of cohort studies, and even smaller when restricted to studies (cohort and case-control designs) deemed as having a low risk of bias. In addition, despite methodological rigor, failure to account for differential use of PSA screening may bias results because patients who have undergone vasectomy are more likely to undergo PSA screening and thus receive a diagnosis of prostate cancer. 33 In our study, the association between vasectomy and prostate cancer held in a subset analysis restricted to studies that accounted for PSA screening. Our analysis illustrates the susceptibility of observational studies to bias and highlights the importance of meticulous study design. More important, simply because a statistically significant association was detected, one cannot confirm with certainty that a causal association exists. Owing to the observational nature of pooled studies, residual unmeasured bias is still possible. Residual detection bias remains an ongoing concern, even though several studies accounted for serum PSA screening and/or contact with the health care system. A recent article by Tangen Although vasectomy may lead to the development of antisperm antibodies, 81 there is no evidence that these antibodies or the subsequent formation of immune complexes leads to prostate cancer. 79 One study found increased cell proliferation 7 days after vasectomy in the ductal system of the rat ventral prostate, 78 although the mechanism remains unclear.
On the other hand, the benefits of vasectomy as a method of contraception must be considered. More than 99% of women who have ever been sexually active have used a form of contraception at some point. 82 However, according to the most recent data, 45%
of pregnancies in 2011 in the United States were unintended 83 ; 41% of these pregnancies occurred among women who used contraception inconsistently.
82 Two-thirds of women using contraception rely on nonpermanent methods, many of which have a higher failure rate with typical use vs perfect use. 84 Meanwhile, 25% of women rely on surgical sterilization for contraception and 8% rely on male surgical sterilization. Given the lower costs and lower risk of complications for vasectomy compared with tubal ligation, 1,2 it is clear that vasectomy is underused and should be offered more routinely to couples seeking a long-term method of contraception.
Strengths and Limitations
There are several strengths to this study, including its size, its comprehensive search strategy in all languages, its careful review for study inclusion, its thorough assessment of study quality, and its use of a priori secondary analyses. This study is the first, to our knowledge, to separately evaluate studies with a low risk of bias and to evaluate high-grade, advanced, and fatal prostate cancers as secondary outcomes. Furthermore, we used relative effect estimates to calculate absolute effect estimates, which are more useful and more readily interpretable for clinicians, policymakers, and patients.
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There are also limitations to our study. First, this metaanalysis is based on observational data because randomized trials are neither presently available nor likely to be performed in the future. As such, the unmeasured biases present in the individual studies must be taken into account. Our analytic approach addressed this issue in part by separately evaluating cross-sectional, case-control, and cohort studies and, additionally, separately evaluating the cohort and case-control studies with a low risk of bias. Second, publication bias cannot be ruled out. On the other hand, publication bias would have had outcomes in opposite directions in case-control and cohort metaanalyses, yet these analyses were consistent with each other. Finally, our analysis cannot definitively prove or disprove causality. However, as already outlined, a strong argument for a causal association between vasectomy and prostate cancer does not exist based on our data and on other existing literature.
Although it is tempting to consider potential avenues of further research on the link between vasectomy and prostate cancer, there are many other research topics that warrant greater priority in a system with finite health care research resources. We have demonstrated that any risk, if present, is sufficiently small that it is unlikely to be of clinical importance. We believe that this meta-analysis, drawing on 3 decades of epidemiologic literature, provides sufficiently robust data to inform clinical care and supports the current guidelines of the American Urological Association. 
Conclusions
Our meta-analysis found a weak association between vasectomy and the risk of prostate cancer among cohort studies with a low risk of bias and a similar but nonsignificant association among case-control studies with a low risk of bias. There was a similar nonsignificant association between vasectomy and high-grade, advanced-stage, or fatal prostate cancer. The association between vasectomy and prostate cancer was stronger when studies with moderate to high risk of bias were included. If assuming a causal association, which is unlikely based on our data and other existing literature, vasectomy would confer only a 5% relative increase or a 0.6% absolute increase in lifetime risk of prostate cancer, and would be responsible for only 0.5% of cases of prostate cancer in the population. Therefore, although patients should be appropriately counseled, concerns about the risk of prostate cancer should not preclude clinicians from offering vasectomy to couples seeking long-term contraception. 26. Roerecke M, Rehm J. Chronic heavy drinking and ischaemic heart disease: a systematic review and meta-analysis. Open Heart. 2014;1 (1) 
